Sprint Bioscience AB (publ) is taking further steps in its DCPS program through a new study that reinforces the scientific support for DCPS inhibition as a promising treatment strategy for acute myeloid leukemia (AML). The study is published in the scientific journal Discover Oncology.

DCPS is an enzyme with a central role in cellular RNA processing, and Sprint Bioscience has previously shown that both cell lines and patient samples are sensitive to DCPS inhibition. The new study, based on samples from 24 AML patients, confirms that low levels of the protein FHIT may serve as a biomarker for identifying patients with particularly strong treatment responses.

The study also shows a clear connection between FHIT and the clinically established biomarker IDH2, where IDH2 mutations frequently coincide with low FHIT levels and consequently increased sensitivity to DCPS inhibitors. Together, these findings strengthen the potential of using biomarkers for patient selection and further support DCPS as a promising and potentially safe target for future AML treatments.

The need for new treatment options for AML remains high, particularly for older patients who often do not respond to or tolerate today’s intensive chemotherapy regimens, leading to frequent relapses.

“The new findings provide strong support for DCPS inhibition and clearly show how FHIT and IDH2 can be used to identify the patients who stand to benefit the most from DCPS-targeted treatment,” said Martin Andersson, Chief Scientific Officer at Sprint Bioscience.

The article is a collaboration between Sprint Bioscience AB (publ), NeoTargets AB, and research groups led by Dr. Julian Walfridsson and Magnus Tobiasson at Karolinska Institutet. It has been partially funded by the Swedish Foundation for Strategic Research through an industrial PhD fellowship.

The article in Discover Oncology is available here: https://link.springer.com/article/10.1007/s12672-026-04880-x

For further information, kindly contact:
Johan Emilsson, CEO, Sprint Bioscience
Phone: +46 (8) 411 44 55
Email: johan.emilsson@sprintbioscience.com

About Sprint Bioscience AB (publ)
Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs enter partnerships through licensing agreements, asset acquisitions, or research collaborations with global pharmaceutical companies during the pre-clinical phase and the company has successfully formed several agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

For further information, kindly contact:

Johan Emilsson, CEO, Sprint Bioscience
Phone: +46 (8) 411 44 55
Email: johan.emilsson@sprintbioscience.com

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs enter partnerships through licensing agreements, asset acquisitions, or research collaborations with global pharmaceutical companies during the pre-clinical phase and the company has successfully formed several agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

Attachments

Sprint Bioscience publishes new research findings that strengthen the potential of DCPS inhibitors in AML

Läs mer på MFN